mTOR Inhibition induces endothelial progenitor cell death

American Journal of Transplantation

Volumn 6, Issue 9, 2006, Pages 2069-2079

  Miriuka, S G ^a   Rao, V ^a   Peterson, M ^a   Tumiati, L ^a   Delgado, D H ^a   Mohan, R ^b   Ramzy, D ^a   Stewart, D ^b,c   Ross, H J ^a   Waddell, T K ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Endothelial progenitor cells; Immunosuppression; mTOR; Rapamycin

Indexed keywords

CASPASE; CATHEPSIN; CYCLOSPORIN A; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; TACROLIMUS;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; TISSUE REPAIR; VASCULAR DISEASE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYCLOSPORINE; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROTEIN KINASES; SIROLIMUS; STEM CELLS; TACROLIMUS;

EID: 33746929488     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01433.x     Document Type: Article

References (35)

1. Urbich C, Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res 2004; 95: 343-353.
2. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003; 108: 2511-2516.
3. Bellik L, Ledda F, Parenti A. Morphological and phenotypical characterization of human endothelial progenitor cells in an early stage of differentiation. FEBS Lett 2005; 579: 2731-2736.
4. Hristov M, Erl W,Weber PC. Endothelial progenitor cells: Isolation and characterization. Trends Cardiovasc Med 2003; 13: 201-206.
5. Ribatti D. The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 2004; 8: 294-300.
6. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-228.
7. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004; 104: 2073-2080.
8. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-340.
9. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
10. Fingar DC, Blenis J. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23: 3151-3171.
11. Riesterer O, Zingg D, Hummerjohann J, Bodis S, Pruschy M. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene 2004; 23: 4624-4635.
12. Kahan BD, Camardo JS. Rapamycin: Clinical results and future opportunities. Transplantation 2001; 72: 1181-1193.
13. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
14. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
15. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3: 371-377.
16. Kalka C, Masuda H, Takahashi T et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86: 1198-1202.
17. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000; 105: 71-77.
18. Stengel D, Antonucci M, Gaoua W et al. Inhibition of LPL expression in human monocyteûderived macrophages is dependent on LDL oxidation state: A key role for lysophosphatidylcholine. Arterioscler Thromb Vasc Biol 1998; 18: 1172-1180.
19. William R,Watson G, Rotstein OD, Parodo J, Bitar R, Marshall JC. The IL-1{beta}-converting enzyme (Caspase-1) inhibits apoptosis of inflammatory neutrophils through activation of IL-1{beta}. J Immunol 1998; 161: 957-962.
20. Munafo DB, Colombo MI. A novel assay to study autophagy: Regulation of autophagosome vacuole size by amino acid deprivation. J Cell Sci 2001; 114: 3619-3629.
21. U.S. Food and Drug Administration. CYPHER™: Summary of safety and effectiveness. http://www.fda.gov/cdrh/PDF2/P020026b.PDF. 2003.
22. Sugatani T, Hruska KA. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 2005; 280: 3583-3589.
23. Woltman AM, van der Kooij SW, Coffer PJ, Offringa R, Daha MR, van Kooten C. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003; 101: 1439-1445.
24. Desai BN, Myers BR, Schreiber SL. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc Natl Acad Sci U S A 2002; 99: 4319-4324.
25. Thyrell L, Hjortsberg L, Arulampalam V et al. Interferon {alpha}-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem 2004; 279: 24152-24162.
26. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the proapoptotic molecule BAD. Proc Natl Acad Sci U S A 2001; 98: 9666-9670.
27. Shinjyo T, Kuribara R, Inukai T et al. Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol 2001; 21: 854-864.
28. Wendel HG, De Stanchina E, Fridman JS et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337.
29. Cuervo AM. Autophagy: Many paths to the same end. Mol Cell Biochem 2004; 263: 55-72.
30. Levine B, Yuan J. Autophagy in cell death: An innocent convict? J Clin Invest 2005; 115: 2679-2688.
31. Ravikumar B, Stewart A, Kita H, Kato K, Duden R, Rubinsztein DC. Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy. Hum Mol Genet 2003; 12: 985-994.
32. Gerber HP, Malik AK, Solar GP et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954-958.
33. Butzal M, Loges S, Schweizer M et al. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 2004; 300: 65-71.
34. Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 2005; 111: 926-931.
35. Costa MA, Simon DI. Molecular basis of restenosis and drugeluting stents. Circulation 2005; 111: 2257-2273.